THERADIGM
DEAD

Serial Number

88443079

Owner

Vesta Therapeutics, Inc.

Attorney

Keith W. Medansky

Filing Date

May 23, 2019

Add to watchlist:

No watchlists yet
View on USPTO

THERADIGM Trademark

Serial Number: 88443079

THERADIGM is a trademark filed by Vesta Therapeutics, Inc. on May 23, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Vesta Therapeutics, Inc. (5 trademarks)

7513 Connelley Drive, Suite I
Hanover, MD 21076

Entity Type: 03

Trademark Details

Filing Date

May 23, 2019

Registration Date

Not Registered

Published for Opposition

October 1, 2019

Goods & Services

Biomanufacturing for others, namely, manufacturing of biologics, cells, scaffolds and matrices, and related biological materials using biological organisms in the manufacturing process

Biologics, namely, cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely, stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism

Biologics, namely, cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely, cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely, cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances

Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism

Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 3, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 2, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 24, 2022 EXRA
SOU EXTENSION 5 GRANTED
May 23, 2022 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 23, 2022 AITU
SOU EXTENSION 5 FILED
May 18, 2022 EXT5
SOU TEAS EXTENSION RECEIVED
May 18, 2022 EEXT
ASSIGNED TO EXAMINER
Jan 28, 2022 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 28, 2021 EXRA
SOU EXTENSION 4 GRANTED
Oct 26, 2021 EX4G
SOU EXTENSION 4 FILED
Oct 26, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 26, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 29, 2021 EXRA
SOU EXTENSION 3 GRANTED
Apr 27, 2021 EX3G
SOU EXTENSION 3 FILED
Apr 27, 2021 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 27, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 18, 2020 EXRA
SOU EXTENSION 2 GRANTED
Nov 16, 2020 EX2G
SOU EXTENSION 2 FILED
Nov 16, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 16, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 9, 2020 EXRA
SOU EXTENSION 1 GRANTED
May 7, 2020 EX1G
SOU EXTENSION 1 FILED
May 7, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
May 7, 2020 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 26, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 1, 2019 NPUB
PUBLISHED FOR OPPOSITION
Oct 1, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 11, 2019 NONP
ASSIGNED TO LIE
Aug 29, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 21, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 19, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 19, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 19, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 19, 2019 CNEA
ASSIGNED TO EXAMINER
Aug 13, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 7, 2019 NWOS
NEW APPLICATION ENTERED
May 27, 2019 NWAP